[
  {
    "objectID": "data_metabolic_syndrome.html",
    "href": "data_metabolic_syndrome.html",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "The study is a comparative analysis of two different models of metabolic syndrome, high fat and high fat+high fructose, in rats using a metabolomic approach.\nThe main questions it attempts to answer are: Which of the two models is more suitable for drawing conclusions about the human pathology of metabolic syndrome? Is there a differentiation of the metabolomic profile between the two dietary models? Is either of the profiles closer to the average metabolic profile of an individual with metabolic syndrome? Does either of the two models reveal early biomarkers? If so, do any of them match known human markers? The experimental models were designed for a duration of 8 weeks, but the study was extended by an additional month.\nThis time extension led to an initial divergence of the metabolomic profiles, but gradual convergence thereafter. The question that arises is whether the final metabolic profile of metabolic syndrome is unique, but the pathways leading to it differ. What is the degree of success of each model in terms of the 5 key features of metabolic syndrome. Regarding the experimental design. The study included two different dietary models to induce metabolic syndrome in rats. The samples were analyzed at various time points (5) metabolomic analysis and biochemical markers. The data collected include hematological, biochemical and metabolomic measurements in blood.\n\n\nData collection occurred in monthly intervals:\nTime point 0: Baseline or pre-treatment\nTime point 1: 1 month after nutrition plan treatment\nTime point 2: 2 months after nutrition plan treatment\nTime point 3: 3 months after nutrition plan treatment\nTime point 4: 3 months after nutrition plan treatment (same as time point 3) but post-mortem measurements using a different blood sample extraction method than in the other time points.\nThe post-mortem clinical data i.e.¬†weight, LDL, triglycerides etc. correspond to time point 4, and therefore match the metabolite data at time point 4. The match will be used to derive surrogate or substitute response variables (from the list of metabolites) for each variable of interest in the clinical data, since for the clinical data there is only 1 measurement in time. This is further described in the modeling page.\nTime point 4 will be excluded from the longitudinal analysis since it was post-mortem.\nAt time point 0 there were differences in the age of rats, and those differences are currently not known. At time point 1, these age differences were corrected by sampling the rat measurements asynchronously. Hence and since time will be a covariate in all models, age is not considered as a covariate i.e.¬†proportional to time since all rats have same age from time point 1. In addition, in order to correct for age differences at time point 0, the models will adjust for metabolites at time point 0.\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†1: Missing values per variable, sorted by the percetange to the total 169 observations. Ten metabolites have more than 20% of their values missing.\n\n\n\n\n\n¬†\n\n\n\n\n\ncase\nmetabolite\n% missing\n\n\n\n\n1\nTheobromine\n53\n\n\n2\nSorbitol\n42\n\n\n3\n4OHProline\n39\n\n\n4\nPyroglutamic\n38\n\n\n5\nInositol\n36\n\n\n6\nGlycolic\n35\n\n\n7\ng_aminobutyric\n29\n\n\n8\nHippuric_Acid\n27\n\n\n9\nHomocysteine\n23\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†2: Missing values per data column.\n\n\n\n\n\n¬†\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: Metabolite concentraion values in data. 0-1 scaled.\n\n\n\n\n\nThe missing values as seen in the data summaries above have been imputed with the value 1 so that the log transformation will result in a 0 value i.e.¬†non-detection. All below data descriptions, statistical tests and graphics are based on the imputed data. The Modeling page also utilizes the data after imputation.\n\n\n\n\n\n\n\n\n\n\nContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Metabolite Data Descriptives\n    \n    \n      75 Continous Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Methylamine\n\n134\n1\n134\n1\n423.4\n357.3\n429.6\n\n\n  19.96    54.88    117.34    271.28    624.71    1078.86    1336.83  \n    Dimethylamine\n\n129\n6\n129\n1\n661.5\n621.7\n570.2\n\n\n  38.83    49.98    90.15    712.11    983.96    1201.95    1403.78  \n    Trimethylamine\n\n127\n8\n127\n1\n955.3\n794.2\n1066\n\n\n  96.51    106.26    163.31    495.52    1457.89    2322.45    3245.75  \n    Glycine\n\n134\n1\n134\n1\n1146\n1030\n746.1\n\n\n  338.9    440.4    677.6    945.8    1358.5    1996.9    2673.4  \n    Trimethylamine_n_oxide\n\n135\n0\n135\n1\n48166\n46355\n34016\n\n\n  10777    14390    24213    41464    67779    87789    96621  \n    Monoisoamylamine\n\n126\n9\n126\n1\n3281\n2672\n3508\n\n\n  61.75    84.39    810.01    2373.42    4203.47    7197.61    9077.04  \n    Putrescine\n\n126\n9\n126\n1\n31378\n30689\n29503\n\n\n  376.6    707.6    1831.4    35904.2    54323.1    63496.5    67917.3  \n    Sarcosine\n\n135\n0\n135\n1\n219714\n219488\n75708\n\n\n  113222    130065    179555    218566    259775    299938    322061  \n    Alanine\n\n135\n0\n135\n1\n181962\n181746\n61484\n\n\n  94170    109583    151493    180672    219886    244448    259827  \n    Cadaverine\n\n119\n16\n119\n1\n194.4\n145.2\n198.2\n\n\n  35.23    42.54    62.17    112.22    248.19    457.80    634.20  \n    Choline\n\n134\n1\n134\n1\n1962193\n1985092\n472384\n\n\n  1065086    1548304    1758390    1985070    2216581    2519395    2544897  \n    g_aminobutyric\n\n96\n39\n96\n1\n689.4\n657.4\n571.6\n\n\n  40.63    69.75    244.99    599.85    1074.41    1405.05    1623.81  \n    Serine\n\n135\n0\n135\n1\n38727\n39120\n15305\n\n\n  13455    20391    29198    39964    46814    55177    60405  \n    Hypotaurine\n\n135\n0\n135\n1\n2960\n2912\n1425\n\n\n  1167    1400    2073    2902    3853    4551    5152  \n    Cytosine\n\n135\n0\n135\n1\n175653\n180133\n60499\n\n\n  71715    100766    148677    183875    213159    234218    246187  \n    Histamine\n\n135\n0\n135\n1\n39717\n31960\n29107\n\n\n  12252    17374    23339    29468    41992    68414    94916  \n    Uracil\n\n134\n1\n134\n1\n7268\n7200\n3879\n\n\n  1912    2893    4650    7204    9862    11483    12005  \n    Creatinine\n\n134\n1\n134\n1\n664888\n596593\n387868\n\n\n  283107    323613    430717    559742    767459    1118355    1283245  \n    Proline\n\n135\n0\n135\n1\n12101\n11901\n5532\n\n\n  5308    6379    8208    12161    14969    19100    21437  \n    Betaine\n\n135\n0\n135\n1\n4275341\n4273391\n1252705\n\n\n  2183312    3196544    3633436    4193768    4973552    5735604    6177199  \n    Norvaline_Valine\n\n135\n0\n135\n1\n282669\n281984\n99595\n\n\n  160441    183282    228670    277629    335779    394766    421021  \n    Threonine\n\n120\n15\n120\n1\n82928\n81463\n41940\n\n\n  32052    41163    54895    79966    105511    127745    154904  \n    Taurine\n\n135\n0\n135\n1\n17216\n17331\n7049\n\n\n  7798    9609    12465    17760    21777    24507    27234  \n    Thymine\n\n135\n0\n135\n1\n5796\n6107\n2061\n\n\n  1081    2472    5218    6199    7134    7633    8124  \n    Pyroglutamic\n\n84\n51\n84\n1\n3763\n2860\n5550\n\n\n  11.31    19.08    54.36    227.94    8304.96    14344.44    15495.60  \n    4OHProline\n\n83\n52\n83\n1\n2298\n2172\n2304\n\n\n  95.52    201.01    380.70    1550.49    3896.50    4806.33    5992.20  \n    Isoleucine\n\n135\n0\n135\n1\n34665\n34943\n12080\n\n\n  14403    20937    29468    34867    40411    49093    51891  \n    Leucine\n\n135\n0\n135\n1\n911203\n889770\n549270\n\n\n  282286    364043    521033    821633    1276641    1554380    1842392  \n    Creatine\n\n135\n0\n135\n1\n850572\n863036\n280966\n\n\n  377778    545055    725328    864268    1005066    1127007    1218109  \n    Asparagine\n\n135\n0\n135\n1\n8943\n8568\n5225\n\n\n  2664    3627    5613    8494    11664    15325    17632  \n    Aspartic_Acid\n\n135\n0\n135\n1\n1773\n1715\n1997\n\n\n  39.96    69.65    153.67    923.68    3253.44    4085.23    5324.57  \n    Adenine\n\n135\n0\n135\n1\n103095\n97434\n68946\n\n\n  12758    35063    58661    97296    132366    178952    209281  \n    Hypoxanthine\n\n134\n1\n134\n1\n936038\n918138\n671574\n\n\n  121502    206919    445774    919651    1366879    1740503    1931342  \n    Anthranilic\n\n116\n19\n116\n1\n736.4\n727.5\n364.7\n\n\n  207.1    316.8    537.4    719.3    953.9    1122.2    1254.7  \n    Glutamine\n\n135\n0\n135\n1\n458006\n439093\n290788\n\n\n  124442    190326    247251    378888    610074    795510    1001633  \n    Lysine\n\n129\n6\n129\n1\n69861\n69889\n75607\n\n\n  744.9    937.6    1678.4    61231.9    126306.9    160549.3    178740.8  \n    Methionine\n\n135\n0\n135\n1\n29887\n28032\n11730\n\n\n  16347    19550    23448    26738    32933    47610    53560  \n    Guanine\n\n110\n25\n110\n1\n22.21\n19.12\n21.56\n\n\n  2.100    3.044    6.374    14.614    30.756    51.083    64.624  \n    Xanthine\n\n131\n4\n131\n1\n41967\n41718\n25829\n\n\n  7433    11655    24411    41070    58730    71539    78269  \n    Allantoin\n\n133\n2\n133\n1\n21337\n21257\n8417\n\n\n  6522    12899    17130    21042    25588    28610    30992  \n    Tryptamine\n\n129\n6\n129\n1\n28.62\n24.79\n25.36\n\n\n  4.105    5.946    10.531    22.130    35.508    57.258    65.890  \n    Phenylalanine\n\n135\n0\n135\n1\n516449\n508093\n166958\n\n\n  263522    349229    438825    498913    587719    708804    785229  \n    3_Methylhistidine\n\n135\n0\n135\n1\n29800\n27832\n29823\n\n\n  810.5    1788.8    6341.4    23229.2    47803.1    61226.2    70634.8  \n    Cotinine\n\n135\n0\n135\n1\n19034\n18915\n12927\n\n\n  2243    4656    9052    18179    28519    34334    37667  \n    Fructose\n\n134\n1\n134\n1\n2471\n2452\n971.3\n\n\n  1117    1457    1950    2460    2924    3518    3812  \n    Theobromine\n\n63\n72\n63\n1\n27.46\n22.49\n26.79\n\n\n  2.196    4.243    9.492    16.884    36.399    71.577    84.793  \n    Tyrosine\n\n135\n0\n135\n1\n24594\n24055\n11224\n\n\n  12336    14112    16597    22589    31604    37578    42225  \n    Mannitol\n\n124\n11\n124\n1\n76.84\n70.37\n63.84\n\n\n  3.253    8.234    33.605    63.437    105.467    155.582    200.262  \n    Caffeine\n\n130\n5\n130\n1\n79.59\n71.97\n69.01\n\n\n  6.41    12.10    31.78    62.95    111.22    145.85    166.13  \n    Acetylcarnitine\n\n135\n0\n135\n1\n3887604\n3851093\n1272483\n\n\n  2406126    2623392    3072928    3737604    4649211    5433679    5872830  \n    Tryptophan\n\n135\n0\n135\n1\n82197\n81686\n29116\n\n\n  45697    52842    62781    84660    100089    112871    122827  \n    Indole_3_Lactic_Acid\n\n127\n8\n127\n1\n43.47\n38.71\n44.44\n\n\n  1.888    2.876    7.343    30.058    66.568    102.035    112.959  \n    Xanthurenic_Acid\n\n115\n20\n115\n1\n81.03\n82.95\n87.55\n\n\n  4.299    5.071    7.771    25.750    156.723    183.876    213.303  \n    5OH_L_Tryptophan\n\n134\n1\n134\n1\n101.7\n100\n40.94\n\n\n  47.50    60.16    80.11    99.30    122.08    150.67    171.81  \n    Thymidine\n\n134\n1\n134\n1\n16919\n17596\n5440\n\n\n  5560    9781    15367    17913    19929    22369    23469  \n    Cytidine\n\n135\n0\n135\n1\n34627\n30424\n33932\n\n\n  8446    9509    10901    15049    53533    77398    116167  \n    Adenosine\n\n133\n2\n133\n1\n539474\n509577\n372788\n\n\n  42119    178147    301811    492637    719130    953744    1113718  \n    Inosine\n\n134\n1\n134\n1\n18941\n18063\n8840\n\n\n  8832    10507    13175    17650    23421    30479    35001  \n    Lactose\n\n123\n12\n123\n1\n44.23\n33.64\n42.9\n\n\n  8.522    9.535    15.714    26.728    59.258    105.604    140.334  \n    Glycolic\n\n88\n47\n88\n1\n12.72\n8.368\n16.61\n\n\n  0.3601    0.6285    1.6980    3.2760    21.9630    41.4577    46.2001  \n    Pyruvic\n\n133\n2\n133\n1\n2086\n2072\n1048\n\n\n  620.8    964.2    1394.3    2092.1    2749.9    3134.6    3656.0  \n    Lactic_Acid\n\n135\n0\n135\n1\n2580\n2591\n1304\n\n\n  590.1    1123.1    1908.5    2550.7    3342.8    4152.8    4502.2  \n    Benzoic_Acid\n\n134\n1\n134\n1\n20.6\n20.76\n7.334\n\n\n  10.20    12.28    17.22    21.21    24.04    29.56    31.51  \n    Homocysteine\n\n104\n31\n104\n1\n11.36\n9.398\n12.06\n\n\n  0.2510    0.5294    3.0005    7.8310    16.2197    30.1079    35.3650  \n    Ribose\n\n135\n0\n135\n1\n58.64\n38.9\n71.37\n\n\n  4.110    5.716    9.588    22.547    78.739    182.974    227.937  \n    Xylitol\n\n113\n22\n113\n1\n4.569\n3.896\n4.647\n\n\n  0.3224    0.4902    1.2120    2.7670    6.4430    11.4452    13.9886  \n    Arabitol\n\n111\n24\n110\n1\n3.359\n2.955\n3.298\n\n\n  0.1960    0.3210    0.9495    2.3630    4.8680    7.6020    9.7850  \n    Ascorbic_Acid\n\n134\n1\n134\n1\n45.19\n44.39\n36.67\n\n\n  1.793    3.345    15.849    45.382    66.610    94.125    102.456  \n    Hippuric_Acid\n\n98\n37\n98\n1\n105.6\n90.96\n145.2\n\n\n  0.2394    0.6285    1.7450    9.0705    198.7158    315.3347    398.7045  \n    Glucose\n\n135\n0\n135\n1\n1790\n1829\n640.5\n\n\n  645.1    988.1    1503.6    1860.6    2151.0    2412.0    2558.7  \n    Mannose\n\n134\n1\n134\n1\n2178\n2290\n1017\n\n\n  375.7    515.2    1773.7    2419.1    2765.3    3160.9    3444.0  \n    Inositol\n\n87\n48\n87\n1\n7.221\n3.821\n9.558\n\n\n  0.2215    0.4726    1.0235    2.5620    7.1655    23.7392    31.3565  \n    Sorbitol\n\n78\n57\n77\n1\n8.037\n3.296\n11.04\n\n\n  0.1477    0.2143    0.7765    2.1340    5.7780    29.2574    32.9332  \n    Uridine\n\n135\n0\n135\n1\n1944\n1954\n914.3\n\n\n  227.1    997.3    1493.6    1950.0    2484.3    2856.8    3327.7  \n    Maltose\n\n110\n25\n110\n1\n6.544\n5.446\n6.76\n\n\n  0.3386    0.7923    1.6010    4.1180    8.7125    15.7619    19.3221  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Metabolite Data Descriptives\n    \n    \n      4 Categorical Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n135\n0\n34\n\n\n\n\n\n\n    Time_Point\nWeek in treatment\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n    NutrMod\nNutritional Model: Controls (normal diet), HC (high carbs diet) and  HFHC (high fat and high carb diet)\n135\n0\n3\n\n\n\n\n\n\n    Month\n\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n  \n  \n  \n\n\n\n\n\n\n\n\nMetabolic syndrome is associated with several metabolites that reflect alterations in glucose, lipid, amino acid, and energy metabolism. Key metabolites include:\n\nLipid Metabolites\n\nTriglycerides (TG): Elevated in metabolic syndrome, indicating impaired fat metabolism. Free fatty acids (FFA): Increased levels contribute to insulin resistance and inflammation. Low-density lipoprotein (LDL) and Very-low-density lipoprotein (VLDL): Higher levels of these ‚Äúbad‚Äù cholesterol types are common. High-density lipoprotein (HDL): Reduced ‚Äúgood‚Äù cholesterol levels are a marker of metabolic syndrome. Ceramides: Bioactive lipids linked to insulin resistance and cardiovascular disease.\n\nGlucose and Energy Metabolites\n\nGlucose: Elevated fasting glucose is a diagnostic marker of metabolic syndrome. Insulin: High levels indicate insulin resistance. Lactate: Increased due to altered glycolysis and mitochondrial dysfunction. Ketone bodies (Œ≤-hydroxybutyrate, acetoacetate): Altered levels indicate disrupted fatty acid oxidation.\n\nAmino Acid Metabolites\n\nBranched-chain amino acids (BCAAs) (Leucine, Isoleucine, Valine): Elevated levels are strongly linked to insulin resistance. Aromatic amino acids (Tyrosine, Phenylalanine): Increased levels are associated with obesity and diabetes risk. Glutamate and Glutamine: Higher glutamate and lower glutamine levels are associated with metabolic dysfunction.\n\nInflammatory and Oxidative Stress Metabolites\n\nC-reactive protein (CRP): A marker of systemic inflammation. Homocysteine: Elevated levels are linked to cardiovascular risk. Oxidized LDL: A marker of oxidative stress and atherosclerosis risk.\n\nGut Microbiome-Derived Metabolites\n\nShort-chain fatty acids (SCFAs) (Butyrate, Acetate, Propionate): Reduced levels may indicate an unhealthy gut microbiome. Trimethylamine-N-oxide (TMAO): Elevated levels are associated with cardiovascular disease risk. These metabolites collectively indicate metabolic dysfunction, insulin resistance, and increased cardiovascular risk. Monitoring and targeting these biomarkers through diet, exercise, and medications can help manage metabolic syndrome.\n‚úÖ Strongly Associated Biomarkers for Metabolic Syndrome:\n\nTrimethylamine N-oxide (TMAO) ‚Äì Elevated levels are linked to cardiovascular disease, insulin resistance, and gut microbiota imbalance.\nCholine ‚Äì Essential for lipid metabolism; imbalances are linked to NAFLD and insulin resistance.\nSerine ‚Äì Low levels are associated with insulin resistance and metabolic dysfunction.\nGlycine ‚Äì Reduced in MetS; involved in antioxidant defense and glucose metabolism.\nAlanine ‚Äì Increased in MetS; involved in gluconeogenesis and insulin resistance.\nIsoleucine ‚Äì Branched-chain amino acid (BCAA) associated with obesity, insulin resistance, and metabolic dysfunction.\nLeucine ‚Äì Elevated levels correlate with MetS, obesity, and T2D.\nCreatinine ‚Äì A marker of muscle metabolism and kidney function, associated with insulin resistance and MetS progression.\nTaurine ‚Äì Linked to lipid metabolism, blood pressure regulation, and oxidative stress.\nBetaine ‚Äì Plays a role in homocysteine metabolism; imbalances can contribute to cardiovascular risk.\nTyrosine ‚Äì Elevated in insulin resistance and metabolic dysfunction.\nPhenylalanine ‚Äì Increased in MetS, linked to impaired glucose metabolism.\nAcetylcarnitine ‚Äì Implicated in fatty acid metabolism dysfunction in MetS.\nFructose ‚Äì High intake contributes to insulin resistance and fatty liver disease.\nGlucose ‚Äì A core biomarker of insulin resistance and diabetes.\nMannose ‚Äì Altered metabolism is linked to insulin resistance.\nLactic Acid ‚Äì Increased in mitochondrial dysfunction and metabolic disorders.\nPyruvic Acid (Pyruvate) ‚Äì Involved in glycolysis; alterations signal metabolic dysfunction.\n\nüü° Moderately Associated Biomarkers (Need Further Validation):\n\nPutrescine & Cadaverine ‚Äì Polyamines linked to gut microbiota and inflammation in MetS.\nSarcosine ‚Äì Related to methylation and lipid metabolism, but its role in MetS is unclear.\nHistamine ‚Äì Involved in inflammatory responses and metabolic homeostasis.\nHypotaurine ‚Äì Precursor to taurine; may help counter oxidative stress in MetS.\nAsparagine ‚Äì Altered levels may reflect amino acid metabolism changes in MetS.\nAspartic Acid ‚Äì May be involved in energy metabolism and oxidative stress.\nMethionine ‚Äì Essential for methylation reactions; altered levels may affect lipid metabolism.\nLysine ‚Äì Essential amino acid; its metabolic disturbances could relate to insulin resistance.\nAnthranilic Acid ‚Äì A metabolite of tryptophan linked to inflammation and gut microbiota.\nIndole-3-Lactic Acid ‚Äì Gut-derived metabolite with possible metabolic and inflammatory implications.\n5-Hydroxy-L-Tryptophan (5OH-L-Tryptophan) ‚Äì A serotonin precursor involved in neuroendocrine and metabolic regulation.\nXanthurenic Acid ‚Äì A tryptophan metabolite associated with insulin resistance and oxidative stress.\nBenzoic Acid ‚Äì Related to gut microbiota metabolism, possibly linked to MetS.\nXanthine & Hypoxanthine ‚Äì Purine metabolism intermediates; increased levels may be linked to oxidative stress and insulin resistance.\n\n‚ùå Less Relevant or Weak Evidence for MetS:\nThese metabolites are less directly linked to metabolic syndrome but may still have indirect roles:\n\nMethylamine, Dimethylamine, Trimethylamine ‚Äì Related to gut metabolism but not primary MetS markers. Monoisoamylamine ‚Äì Limited data on its role in MetS.\nCytosine, Uracil, Thymine, Adenine, Guanine, Cytidine, Thymidine, Adenosine, Inosine, Uridine, Maltose, Ribose, Xylitol, Arabitol ‚Äì These are nucleotides and sugars with limited direct associations to MetS.\nCaffeine ‚Äì May have protective effects against MetS but is not a biomarker.\nCotinine ‚Äì A nicotine metabolite, not directly related to MetS.\nMannitol, Lactose, Ascorbic Acid (Vitamin C) ‚Äì Not considered primary biomarkers for MetS.\n\nüìå Summary:\nStrongest biomarkers: TMAO, Choline, Serine, Glycine, Alanine, BCAAs (Isoleucine, Leucine), Taurine, Betaine, Acetylcarnitine, Glucose, Lactic Acid, Fructose.\nModerate biomarkers: Polyamines (Putrescine, Cadaverine), Tryptophan metabolites, Histamine, Hypotaurine.\nLess relevant metabolites: Nucleotides, sugar alcohols, caffeine.\n\n\n\n\nüìå Summary: Best Predictors of TMAO\nüî• Strongest Predictors: Choline, Betaine, Carnitine (Acetylcarnitine), Trimethylamine, Dimethylamine, Methylamine\nüü° Moderate Predictors: Serine, Methionine, Glycine, Taurine, Creatinine, Histamine, Hypotaurine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Choline\nüî• Strongest Predictors: Betaine, Serine, Methionine, Glycine, Acetylcarnitine\nüü° Moderate Predictors: Trimethylamine, Dimethylamine, Methylamine, Taurine, Histamine, Creatinine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Serine\nüî• Strongest Predictors: Glycine, Methionine, Asparagine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Choline, Betaine, Taurine, Histamine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Creatinine\n\n\n\nüìå Summary: Best Predictors of Glycine\nüî• Strongest Predictors: Serine, Methionine, Choline, Betaine, Glutamine, Aspartic Acid\nüü° Moderate Predictors: Taurine, Histamine, Acetylcarnitine, Creatinine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine\n\n\n\nüìå Summary: Best Predictors of Alanine\nüî• Strongest Predictors: Pyruvic Acid, Aspartic Acid, Glutamine, Glutamate, Lactic Acid, Asparagine\nüü° Moderate Predictors: Serine, Glycine, Methionine, Creatinine, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine, Taurine\n\n\n\nüìå Summary: Best Predictors of Isoleucine\nüî• Strongest Predictors: Leucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Leucine\nüî• Strongest Predictors: Isoleucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Creatinine\nüî• Strongest Predictors: Creatine, Isoleucine, Leucine, Alanine, Glutamine, Glutamate\nüü° Moderate Predictors: Valine, Methionine, Aspartic Acid, Pyruvic Acid, Lactic Acid, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\nüìå Summary: Best Predictors of Taurine\nüî• Strongest Predictors: Methionine, Hypotaurine, Glutamine, Glutamate, Aspartic Acid\nüü° Moderate Predictors: Serine, Alanine, Creatinine, Glucose, Fructose, Lactic Acid, Pyruvic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†4: Correlation plot of metabolites considering all time points and nutrition models. In general the correlations are positive and high, which might be expected as the majority of data points correspond to one of the two nutrition models i.e.¬†metabolite concentrations are overall affected by the diet treatment.\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\n\n\nNotable cases: [[plot_number]] Metabolite:\n\n[[11]] Choline\n[[12]] g_aminobutyric\n[[14]] Hypotaurine\n[[18]] Creatinine\n[[21]] Norvaline_Valine\n[[23]] Taurine\n[[28]] Leucine\n[[33]] Hypoxanthine\n[[42]] Phenylalanine\n[[51]] Tryptophan\n[[55]] Thymidine\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n[[24]]\n\n\n\n\n\n\n\n\n\n\n[[25]]\n\n\n\n\n\n\n\n\n\n\n[[26]]\n\n\n\n\n\n\n\n\n\n\n[[27]]\n\n\n\n\n\n\n\n\n\n\n[[28]]\n\n\n\n\n\n\n\n\n\n\n[[29]]\n\n\n\n\n\n\n\n\n\n\n[[30]]\n\n\n\n\n\n\n\n\n\n\n[[31]]\n\n\n\n\n\n\n\n\n\n\n[[32]]\n\n\n\n\n\n\n\n\n\n\n[[33]]\n\n\n\n\n\n\n\n\n\n\n[[34]]\n\n\n\n\n\n\n\n\n\n\n[[35]]\n\n\n\n\n\n\n\n\n\n\n[[36]]\n\n\n\n\n\n\n\n\n\n\n[[37]]\n\n\n\n\n\n\n\n\n\n\n[[38]]\n\n\n\n\n\n\n\n\n\n\n[[39]]\n\n\n\n\n\n\n\n\n\n\n[[40]]\n\n\n\n\n\n\n\n\n\n\n[[41]]\n\n\n\n\n\n\n\n\n\n\n[[42]]\n\n\n\n\n\n\n\n\n\n\n[[43]]\n\n\n\n\n\n\n\n\n\n\n[[44]]\n\n\n\n\n\n\n\n\n\n\n[[45]]\n\n\n\n\n\n\n\n\n\n\n[[46]]\n\n\n\n\n\n\n\n\n\n\n[[47]]\n\n\n\n\n\n\n\n\n\n\n[[48]]\n\n\n\n\n\n\n\n\n\n\n[[49]]\n\n\n\n\n\n\n\n\n\n\n[[50]]\n\n\n\n\n\n\n\n\n\n\n[[51]]\n\n\n\n\n\n\n\n\n\n\n[[52]]\n\n\n\n\n\n\n\n\n\n\n[[53]]\n\n\n\n\n\n\n\n\n\n\n[[54]]\n\n\n\n\n\n\n\n\n\n\n[[55]]\n\n\n\n\n\n\n\n\n\n\n[[56]]\n\n\n\n\n\n\n\n\n\n\n[[57]]\n\n\n\n\n\n\n\n\n\n\n[[58]]\n\n\n\n\n\n\n\n\n\n\n[[59]]\n\n\n\n\n\n\n\n\n\n\n[[60]]\n\n\n\n\n\n\n\n\n\n\n[[61]]\n\n\n\n\n\n\n\n\n\n\n[[62]]\n\n\n\n\n\n\n\n\n\n\n[[63]]\n\n\n\n\n\n\n\n\n\n\n[[64]]\n\n\n\n\n\n\n\n\n\n\n[[65]]\n\n\n\n\n\n\n\n\n\n\n[[66]]\n\n\n\n\n\n\n\n\n\n\n[[67]]\n\n\n\n\n\n\n\n\n\n\n[[68]]\n\n\n\n\n\n\n\n\n\n\n[[69]]\n\n\n\n\n\n\n\n\n\n\n[[70]]\n\n\n\n\n\n\n\n\n\n\n[[71]]\n\n\n\n\n\n\n\n\n\n\n[[72]]\n\n\n\n\n\n\n\n\n\n\n[[73]]\n\n\n\n\n\n\n\n\n\n\n[[74]]\n\n\n\n\n\n\n\n\n\n\n[[75]]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      22 Continous Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Glucose\n\n34\n0\n27\n0.999\n149.7\n146.5\n25.54\n\n\n  118.6    131.3    140.0    146.0    153.8    181.3    202.1  \n    Glucose_œÑŒ±ŒπŒΩŒØŒµœÇ\n\n34\n0\n23\n0.997\n136.9\n137.5\n13.55\n\n\n  114.2    125.3    131.0    139.0    143.0    149.7    154.7  \n    Weight\n\n34\n0\n30\n0.999\n468.4\n463.5\n48.08\n\n\n  414.0    422.3    435.0    458.5    487.2    515.4    549.3  \n    BUN\n\n34\n0\n18\n0.996\n35.56\n31.5\n13.05\n\n\n  25.65    26.00    28.00    31.00    34.75    38.40    42.75  \n    Uric_Œëcid\n\n34\n0\n13\n0.988\n1.318\n1.25\n0.4364\n\n\n  0.800    0.860    1.025    1.250    1.475    1.800    2.105  \n    Creatinine\n\n34\n0\n14\n0.985\n0.4924\n0.435\n0.1554\n\n\n  0.380    0.393    0.410    0.425    0.460    0.490    0.497  \n    Tchol\n\n34\n0\n30\n0.999\n126.1\n124.5\n35.94\n\n\n  86.25    91.30    97.75    125.00    148.75    160.80    180.15  \n    Triglycerides\n\n32\n2\n30\n1.000\n267\n243.8\n174.9\n\n\n  90.2    115.7    148.0    231.0    320.0    496.1    597.2  \n    HDL\n\n34\n0\n23\n0.998\n36.94\n36.5\n10.47\n\n\n  24.30    27.30    30.25    35.00    41.75    48.00    54.40  \n    LDL\n\n34\n0\n14\n0.987\n9.147\n9\n3.995\n\n\n  5.00    5.30    7.00    8.00    11.75    14.70    16.00  \n    VLDL\n\n34\n0\n28\n0.999\n52.97\n48.5\n34.5\n\n\n  18.25    23.30    29.25    46.00    65.25    95.00    118.75  \n    TGL_HDL_ratio\n\n32\n2\n31\n1.000\n7.588\n6.37\n5.321\n\n\n  2.776    3.390    4.330    5.600    8.508    12.689    15.953  \n    Atherogenic_Index\n\n32\n2\n27\n0.999\n0.7975\n0.78\n0.2801\n\n\n  0.4415    0.5310    0.6375    0.7500    0.9275    1.1000    1.2015  \n    AST\n\n34\n0\n31\n1.000\n116.1\n107.5\n48.4\n\n\n  72.30    74.30    87.25    102.00    125.75    157.70    189.95  \n    ALT\n\n34\n0\n25\n0.998\n36.59\n36.5\n12.15\n\n\n  23.3    24.0    27.0    37.0    43.0    49.7    52.7  \n    ALP\n\n34\n0\n30\n0.999\n130.9\n129\n41.33\n\n\n  90.65    91.30    100.50    121.50    159.00    185.40    188.10  \n    ALB\n\n34\n0\n11\n0.975\n3.324\n3.35\n0.2909\n\n\n  2.965    3.030    3.200    3.350    3.475    3.670    3.700  \n    FERRITIN\n\n34\n0\n34\n1.000\n7.151\n6.97\n2.973\n\n\n  3.903    4.061    5.380    6.610    8.705    10.425    11.817  \n    LDH\n\n34\n0\n31\n1.000\n567.9\n537\n210.7\n\n\n  336.6    369.3    450.8    520.0    627.8    872.5    993.8  \n    AMYLASE\n\n34\n0\n34\n1.000\n2119\n2136\n373.4\n\n\n  1578    1719    1916    2176    2358    2496    2564  \n    Mg\n\n34\n0\n29\n0.999\n2.833\n2.77\n0.3814\n\n\n  2.497    2.520    2.590    2.755    2.962    3.074    3.131  \n    D3\n\n34\n0\n33\n1.000\n41.5\n41.75\n6.52\n\n\n  31.97    33.26    38.75    41.85    45.88    48.94    49.24  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      3 Categorical Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n34\n0\n34\n\n\n\n\n\n\n    NutrMod\n\n34\n0\n3\n0.876\n2.147\n2\n0.8574\n\n\n    Na\n\n34\n0\n9\n0.953\n145.3\n145\n2.005\n\n\n  \n  \n  \n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\nNotable cases: [[plot_number]] Clinical Metric:\n\n[[7]] Tchol\n[[9]] HDL\n[[10]] LDL\n[[11]] VLDL\n[[15]] ALT\n[[16]] ALP\n[[20]] Amylase\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.05\\) for all nutritional model comparisons but separately for each metabolite.\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n\n\nSee the Modeling page for both a univariate and multivariate analysis on lipids collected at post-mortem stage, as well as their differences amongst the nutritional models.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#notes-quick-descriptives",
    "href": "data_metabolic_syndrome.html#notes-quick-descriptives",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Data collection occurred in monthly intervals:\nTime point 0: Baseline or pre-treatment\nTime point 1: 1 month after nutrition plan treatment\nTime point 2: 2 months after nutrition plan treatment\nTime point 3: 3 months after nutrition plan treatment\nTime point 4: 3 months after nutrition plan treatment (same as time point 3) but post-mortem measurements using a different blood sample extraction method than in the other time points.\nThe post-mortem clinical data i.e.¬†weight, LDL, triglycerides etc. correspond to time point 4, and therefore match the metabolite data at time point 4. The match will be used to derive surrogate or substitute response variables (from the list of metabolites) for each variable of interest in the clinical data, since for the clinical data there is only 1 measurement in time. This is further described in the modeling page.\nTime point 4 will be excluded from the longitudinal analysis since it was post-mortem.\nAt time point 0 there were differences in the age of rats, and those differences are currently not known. At time point 1, these age differences were corrected by sampling the rat measurements asynchronously. Hence and since time will be a covariate in all models, age is not considered as a covariate i.e.¬†proportional to time since all rats have same age from time point 1. In addition, in order to correct for age differences at time point 0, the models will adjust for metabolites at time point 0.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-imputation",
    "href": "data_metabolic_syndrome.html#metabolite-data-imputation",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Figure¬†1: Missing values per variable, sorted by the percetange to the total 169 observations. Ten metabolites have more than 20% of their values missing.\n\n\n\n\n\n¬†\n\n\n\n\n\ncase\nmetabolite\n% missing\n\n\n\n\n1\nTheobromine\n53\n\n\n2\nSorbitol\n42\n\n\n3\n4OHProline\n39\n\n\n4\nPyroglutamic\n38\n\n\n5\nInositol\n36\n\n\n6\nGlycolic\n35\n\n\n7\ng_aminobutyric\n29\n\n\n8\nHippuric_Acid\n27\n\n\n9\nHomocysteine\n23\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†2: Missing values per data column.\n\n\n\n\n\n¬†\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: Metabolite concentraion values in data. 0-1 scaled.\n\n\n\n\n\nThe missing values as seen in the data summaries above have been imputed with the value 1 so that the log transformation will result in a 0 value i.e.¬†non-detection. All below data descriptions, statistical tests and graphics are based on the imputed data. The Modeling page also utilizes the data after imputation.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-summaries",
    "href": "data_metabolic_syndrome.html#metabolite-data-summaries",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "ContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Metabolite Data Descriptives\n    \n    \n      75 Continous Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Methylamine\n\n134\n1\n134\n1\n423.4\n357.3\n429.6\n\n\n  19.96    54.88    117.34    271.28    624.71    1078.86    1336.83  \n    Dimethylamine\n\n129\n6\n129\n1\n661.5\n621.7\n570.2\n\n\n  38.83    49.98    90.15    712.11    983.96    1201.95    1403.78  \n    Trimethylamine\n\n127\n8\n127\n1\n955.3\n794.2\n1066\n\n\n  96.51    106.26    163.31    495.52    1457.89    2322.45    3245.75  \n    Glycine\n\n134\n1\n134\n1\n1146\n1030\n746.1\n\n\n  338.9    440.4    677.6    945.8    1358.5    1996.9    2673.4  \n    Trimethylamine_n_oxide\n\n135\n0\n135\n1\n48166\n46355\n34016\n\n\n  10777    14390    24213    41464    67779    87789    96621  \n    Monoisoamylamine\n\n126\n9\n126\n1\n3281\n2672\n3508\n\n\n  61.75    84.39    810.01    2373.42    4203.47    7197.61    9077.04  \n    Putrescine\n\n126\n9\n126\n1\n31378\n30689\n29503\n\n\n  376.6    707.6    1831.4    35904.2    54323.1    63496.5    67917.3  \n    Sarcosine\n\n135\n0\n135\n1\n219714\n219488\n75708\n\n\n  113222    130065    179555    218566    259775    299938    322061  \n    Alanine\n\n135\n0\n135\n1\n181962\n181746\n61484\n\n\n  94170    109583    151493    180672    219886    244448    259827  \n    Cadaverine\n\n119\n16\n119\n1\n194.4\n145.2\n198.2\n\n\n  35.23    42.54    62.17    112.22    248.19    457.80    634.20  \n    Choline\n\n134\n1\n134\n1\n1962193\n1985092\n472384\n\n\n  1065086    1548304    1758390    1985070    2216581    2519395    2544897  \n    g_aminobutyric\n\n96\n39\n96\n1\n689.4\n657.4\n571.6\n\n\n  40.63    69.75    244.99    599.85    1074.41    1405.05    1623.81  \n    Serine\n\n135\n0\n135\n1\n38727\n39120\n15305\n\n\n  13455    20391    29198    39964    46814    55177    60405  \n    Hypotaurine\n\n135\n0\n135\n1\n2960\n2912\n1425\n\n\n  1167    1400    2073    2902    3853    4551    5152  \n    Cytosine\n\n135\n0\n135\n1\n175653\n180133\n60499\n\n\n  71715    100766    148677    183875    213159    234218    246187  \n    Histamine\n\n135\n0\n135\n1\n39717\n31960\n29107\n\n\n  12252    17374    23339    29468    41992    68414    94916  \n    Uracil\n\n134\n1\n134\n1\n7268\n7200\n3879\n\n\n  1912    2893    4650    7204    9862    11483    12005  \n    Creatinine\n\n134\n1\n134\n1\n664888\n596593\n387868\n\n\n  283107    323613    430717    559742    767459    1118355    1283245  \n    Proline\n\n135\n0\n135\n1\n12101\n11901\n5532\n\n\n  5308    6379    8208    12161    14969    19100    21437  \n    Betaine\n\n135\n0\n135\n1\n4275341\n4273391\n1252705\n\n\n  2183312    3196544    3633436    4193768    4973552    5735604    6177199  \n    Norvaline_Valine\n\n135\n0\n135\n1\n282669\n281984\n99595\n\n\n  160441    183282    228670    277629    335779    394766    421021  \n    Threonine\n\n120\n15\n120\n1\n82928\n81463\n41940\n\n\n  32052    41163    54895    79966    105511    127745    154904  \n    Taurine\n\n135\n0\n135\n1\n17216\n17331\n7049\n\n\n  7798    9609    12465    17760    21777    24507    27234  \n    Thymine\n\n135\n0\n135\n1\n5796\n6107\n2061\n\n\n  1081    2472    5218    6199    7134    7633    8124  \n    Pyroglutamic\n\n84\n51\n84\n1\n3763\n2860\n5550\n\n\n  11.31    19.08    54.36    227.94    8304.96    14344.44    15495.60  \n    4OHProline\n\n83\n52\n83\n1\n2298\n2172\n2304\n\n\n  95.52    201.01    380.70    1550.49    3896.50    4806.33    5992.20  \n    Isoleucine\n\n135\n0\n135\n1\n34665\n34943\n12080\n\n\n  14403    20937    29468    34867    40411    49093    51891  \n    Leucine\n\n135\n0\n135\n1\n911203\n889770\n549270\n\n\n  282286    364043    521033    821633    1276641    1554380    1842392  \n    Creatine\n\n135\n0\n135\n1\n850572\n863036\n280966\n\n\n  377778    545055    725328    864268    1005066    1127007    1218109  \n    Asparagine\n\n135\n0\n135\n1\n8943\n8568\n5225\n\n\n  2664    3627    5613    8494    11664    15325    17632  \n    Aspartic_Acid\n\n135\n0\n135\n1\n1773\n1715\n1997\n\n\n  39.96    69.65    153.67    923.68    3253.44    4085.23    5324.57  \n    Adenine\n\n135\n0\n135\n1\n103095\n97434\n68946\n\n\n  12758    35063    58661    97296    132366    178952    209281  \n    Hypoxanthine\n\n134\n1\n134\n1\n936038\n918138\n671574\n\n\n  121502    206919    445774    919651    1366879    1740503    1931342  \n    Anthranilic\n\n116\n19\n116\n1\n736.4\n727.5\n364.7\n\n\n  207.1    316.8    537.4    719.3    953.9    1122.2    1254.7  \n    Glutamine\n\n135\n0\n135\n1\n458006\n439093\n290788\n\n\n  124442    190326    247251    378888    610074    795510    1001633  \n    Lysine\n\n129\n6\n129\n1\n69861\n69889\n75607\n\n\n  744.9    937.6    1678.4    61231.9    126306.9    160549.3    178740.8  \n    Methionine\n\n135\n0\n135\n1\n29887\n28032\n11730\n\n\n  16347    19550    23448    26738    32933    47610    53560  \n    Guanine\n\n110\n25\n110\n1\n22.21\n19.12\n21.56\n\n\n  2.100    3.044    6.374    14.614    30.756    51.083    64.624  \n    Xanthine\n\n131\n4\n131\n1\n41967\n41718\n25829\n\n\n  7433    11655    24411    41070    58730    71539    78269  \n    Allantoin\n\n133\n2\n133\n1\n21337\n21257\n8417\n\n\n  6522    12899    17130    21042    25588    28610    30992  \n    Tryptamine\n\n129\n6\n129\n1\n28.62\n24.79\n25.36\n\n\n  4.105    5.946    10.531    22.130    35.508    57.258    65.890  \n    Phenylalanine\n\n135\n0\n135\n1\n516449\n508093\n166958\n\n\n  263522    349229    438825    498913    587719    708804    785229  \n    3_Methylhistidine\n\n135\n0\n135\n1\n29800\n27832\n29823\n\n\n  810.5    1788.8    6341.4    23229.2    47803.1    61226.2    70634.8  \n    Cotinine\n\n135\n0\n135\n1\n19034\n18915\n12927\n\n\n  2243    4656    9052    18179    28519    34334    37667  \n    Fructose\n\n134\n1\n134\n1\n2471\n2452\n971.3\n\n\n  1117    1457    1950    2460    2924    3518    3812  \n    Theobromine\n\n63\n72\n63\n1\n27.46\n22.49\n26.79\n\n\n  2.196    4.243    9.492    16.884    36.399    71.577    84.793  \n    Tyrosine\n\n135\n0\n135\n1\n24594\n24055\n11224\n\n\n  12336    14112    16597    22589    31604    37578    42225  \n    Mannitol\n\n124\n11\n124\n1\n76.84\n70.37\n63.84\n\n\n  3.253    8.234    33.605    63.437    105.467    155.582    200.262  \n    Caffeine\n\n130\n5\n130\n1\n79.59\n71.97\n69.01\n\n\n  6.41    12.10    31.78    62.95    111.22    145.85    166.13  \n    Acetylcarnitine\n\n135\n0\n135\n1\n3887604\n3851093\n1272483\n\n\n  2406126    2623392    3072928    3737604    4649211    5433679    5872830  \n    Tryptophan\n\n135\n0\n135\n1\n82197\n81686\n29116\n\n\n  45697    52842    62781    84660    100089    112871    122827  \n    Indole_3_Lactic_Acid\n\n127\n8\n127\n1\n43.47\n38.71\n44.44\n\n\n  1.888    2.876    7.343    30.058    66.568    102.035    112.959  \n    Xanthurenic_Acid\n\n115\n20\n115\n1\n81.03\n82.95\n87.55\n\n\n  4.299    5.071    7.771    25.750    156.723    183.876    213.303  \n    5OH_L_Tryptophan\n\n134\n1\n134\n1\n101.7\n100\n40.94\n\n\n  47.50    60.16    80.11    99.30    122.08    150.67    171.81  \n    Thymidine\n\n134\n1\n134\n1\n16919\n17596\n5440\n\n\n  5560    9781    15367    17913    19929    22369    23469  \n    Cytidine\n\n135\n0\n135\n1\n34627\n30424\n33932\n\n\n  8446    9509    10901    15049    53533    77398    116167  \n    Adenosine\n\n133\n2\n133\n1\n539474\n509577\n372788\n\n\n  42119    178147    301811    492637    719130    953744    1113718  \n    Inosine\n\n134\n1\n134\n1\n18941\n18063\n8840\n\n\n  8832    10507    13175    17650    23421    30479    35001  \n    Lactose\n\n123\n12\n123\n1\n44.23\n33.64\n42.9\n\n\n  8.522    9.535    15.714    26.728    59.258    105.604    140.334  \n    Glycolic\n\n88\n47\n88\n1\n12.72\n8.368\n16.61\n\n\n  0.3601    0.6285    1.6980    3.2760    21.9630    41.4577    46.2001  \n    Pyruvic\n\n133\n2\n133\n1\n2086\n2072\n1048\n\n\n  620.8    964.2    1394.3    2092.1    2749.9    3134.6    3656.0  \n    Lactic_Acid\n\n135\n0\n135\n1\n2580\n2591\n1304\n\n\n  590.1    1123.1    1908.5    2550.7    3342.8    4152.8    4502.2  \n    Benzoic_Acid\n\n134\n1\n134\n1\n20.6\n20.76\n7.334\n\n\n  10.20    12.28    17.22    21.21    24.04    29.56    31.51  \n    Homocysteine\n\n104\n31\n104\n1\n11.36\n9.398\n12.06\n\n\n  0.2510    0.5294    3.0005    7.8310    16.2197    30.1079    35.3650  \n    Ribose\n\n135\n0\n135\n1\n58.64\n38.9\n71.37\n\n\n  4.110    5.716    9.588    22.547    78.739    182.974    227.937  \n    Xylitol\n\n113\n22\n113\n1\n4.569\n3.896\n4.647\n\n\n  0.3224    0.4902    1.2120    2.7670    6.4430    11.4452    13.9886  \n    Arabitol\n\n111\n24\n110\n1\n3.359\n2.955\n3.298\n\n\n  0.1960    0.3210    0.9495    2.3630    4.8680    7.6020    9.7850  \n    Ascorbic_Acid\n\n134\n1\n134\n1\n45.19\n44.39\n36.67\n\n\n  1.793    3.345    15.849    45.382    66.610    94.125    102.456  \n    Hippuric_Acid\n\n98\n37\n98\n1\n105.6\n90.96\n145.2\n\n\n  0.2394    0.6285    1.7450    9.0705    198.7158    315.3347    398.7045  \n    Glucose\n\n135\n0\n135\n1\n1790\n1829\n640.5\n\n\n  645.1    988.1    1503.6    1860.6    2151.0    2412.0    2558.7  \n    Mannose\n\n134\n1\n134\n1\n2178\n2290\n1017\n\n\n  375.7    515.2    1773.7    2419.1    2765.3    3160.9    3444.0  \n    Inositol\n\n87\n48\n87\n1\n7.221\n3.821\n9.558\n\n\n  0.2215    0.4726    1.0235    2.5620    7.1655    23.7392    31.3565  \n    Sorbitol\n\n78\n57\n77\n1\n8.037\n3.296\n11.04\n\n\n  0.1477    0.2143    0.7765    2.1340    5.7780    29.2574    32.9332  \n    Uridine\n\n135\n0\n135\n1\n1944\n1954\n914.3\n\n\n  227.1    997.3    1493.6    1950.0    2484.3    2856.8    3327.7  \n    Maltose\n\n110\n25\n110\n1\n6.544\n5.446\n6.76\n\n\n  0.3386    0.7923    1.6010    4.1180    8.7125    15.7619    19.3221  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Metabolite Data Descriptives\n    \n    \n      4 Categorical Variables of 79 Variables, 135 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n135\n0\n34\n\n\n\n\n\n\n    Time_Point\nWeek in treatment\n135\n0\n4\n0.938\n1.496\n1.5\n1.263\n\n\n    NutrMod\nNutritional Model: Controls (normal diet), HC (high carbs diet) and  HFHC (high fat and high carb diet)\n135\n0\n3\n\n\n\n\n\n\n    Month\n\n135\n0\n4\n0.938\n1.496\n1.5\n1.263",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#metabolite-data-descriptions-eda",
    "href": "data_metabolic_syndrome.html#metabolite-data-descriptions-eda",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Metabolic syndrome is associated with several metabolites that reflect alterations in glucose, lipid, amino acid, and energy metabolism. Key metabolites include:\n\nLipid Metabolites\n\nTriglycerides (TG): Elevated in metabolic syndrome, indicating impaired fat metabolism. Free fatty acids (FFA): Increased levels contribute to insulin resistance and inflammation. Low-density lipoprotein (LDL) and Very-low-density lipoprotein (VLDL): Higher levels of these ‚Äúbad‚Äù cholesterol types are common. High-density lipoprotein (HDL): Reduced ‚Äúgood‚Äù cholesterol levels are a marker of metabolic syndrome. Ceramides: Bioactive lipids linked to insulin resistance and cardiovascular disease.\n\nGlucose and Energy Metabolites\n\nGlucose: Elevated fasting glucose is a diagnostic marker of metabolic syndrome. Insulin: High levels indicate insulin resistance. Lactate: Increased due to altered glycolysis and mitochondrial dysfunction. Ketone bodies (Œ≤-hydroxybutyrate, acetoacetate): Altered levels indicate disrupted fatty acid oxidation.\n\nAmino Acid Metabolites\n\nBranched-chain amino acids (BCAAs) (Leucine, Isoleucine, Valine): Elevated levels are strongly linked to insulin resistance. Aromatic amino acids (Tyrosine, Phenylalanine): Increased levels are associated with obesity and diabetes risk. Glutamate and Glutamine: Higher glutamate and lower glutamine levels are associated with metabolic dysfunction.\n\nInflammatory and Oxidative Stress Metabolites\n\nC-reactive protein (CRP): A marker of systemic inflammation. Homocysteine: Elevated levels are linked to cardiovascular risk. Oxidized LDL: A marker of oxidative stress and atherosclerosis risk.\n\nGut Microbiome-Derived Metabolites\n\nShort-chain fatty acids (SCFAs) (Butyrate, Acetate, Propionate): Reduced levels may indicate an unhealthy gut microbiome. Trimethylamine-N-oxide (TMAO): Elevated levels are associated with cardiovascular disease risk. These metabolites collectively indicate metabolic dysfunction, insulin resistance, and increased cardiovascular risk. Monitoring and targeting these biomarkers through diet, exercise, and medications can help manage metabolic syndrome.\n‚úÖ Strongly Associated Biomarkers for Metabolic Syndrome:\n\nTrimethylamine N-oxide (TMAO) ‚Äì Elevated levels are linked to cardiovascular disease, insulin resistance, and gut microbiota imbalance.\nCholine ‚Äì Essential for lipid metabolism; imbalances are linked to NAFLD and insulin resistance.\nSerine ‚Äì Low levels are associated with insulin resistance and metabolic dysfunction.\nGlycine ‚Äì Reduced in MetS; involved in antioxidant defense and glucose metabolism.\nAlanine ‚Äì Increased in MetS; involved in gluconeogenesis and insulin resistance.\nIsoleucine ‚Äì Branched-chain amino acid (BCAA) associated with obesity, insulin resistance, and metabolic dysfunction.\nLeucine ‚Äì Elevated levels correlate with MetS, obesity, and T2D.\nCreatinine ‚Äì A marker of muscle metabolism and kidney function, associated with insulin resistance and MetS progression.\nTaurine ‚Äì Linked to lipid metabolism, blood pressure regulation, and oxidative stress.\nBetaine ‚Äì Plays a role in homocysteine metabolism; imbalances can contribute to cardiovascular risk.\nTyrosine ‚Äì Elevated in insulin resistance and metabolic dysfunction.\nPhenylalanine ‚Äì Increased in MetS, linked to impaired glucose metabolism.\nAcetylcarnitine ‚Äì Implicated in fatty acid metabolism dysfunction in MetS.\nFructose ‚Äì High intake contributes to insulin resistance and fatty liver disease.\nGlucose ‚Äì A core biomarker of insulin resistance and diabetes.\nMannose ‚Äì Altered metabolism is linked to insulin resistance.\nLactic Acid ‚Äì Increased in mitochondrial dysfunction and metabolic disorders.\nPyruvic Acid (Pyruvate) ‚Äì Involved in glycolysis; alterations signal metabolic dysfunction.\n\nüü° Moderately Associated Biomarkers (Need Further Validation):\n\nPutrescine & Cadaverine ‚Äì Polyamines linked to gut microbiota and inflammation in MetS.\nSarcosine ‚Äì Related to methylation and lipid metabolism, but its role in MetS is unclear.\nHistamine ‚Äì Involved in inflammatory responses and metabolic homeostasis.\nHypotaurine ‚Äì Precursor to taurine; may help counter oxidative stress in MetS.\nAsparagine ‚Äì Altered levels may reflect amino acid metabolism changes in MetS.\nAspartic Acid ‚Äì May be involved in energy metabolism and oxidative stress.\nMethionine ‚Äì Essential for methylation reactions; altered levels may affect lipid metabolism.\nLysine ‚Äì Essential amino acid; its metabolic disturbances could relate to insulin resistance.\nAnthranilic Acid ‚Äì A metabolite of tryptophan linked to inflammation and gut microbiota.\nIndole-3-Lactic Acid ‚Äì Gut-derived metabolite with possible metabolic and inflammatory implications.\n5-Hydroxy-L-Tryptophan (5OH-L-Tryptophan) ‚Äì A serotonin precursor involved in neuroendocrine and metabolic regulation.\nXanthurenic Acid ‚Äì A tryptophan metabolite associated with insulin resistance and oxidative stress.\nBenzoic Acid ‚Äì Related to gut microbiota metabolism, possibly linked to MetS.\nXanthine & Hypoxanthine ‚Äì Purine metabolism intermediates; increased levels may be linked to oxidative stress and insulin resistance.\n\n‚ùå Less Relevant or Weak Evidence for MetS:\nThese metabolites are less directly linked to metabolic syndrome but may still have indirect roles:\n\nMethylamine, Dimethylamine, Trimethylamine ‚Äì Related to gut metabolism but not primary MetS markers. Monoisoamylamine ‚Äì Limited data on its role in MetS.\nCytosine, Uracil, Thymine, Adenine, Guanine, Cytidine, Thymidine, Adenosine, Inosine, Uridine, Maltose, Ribose, Xylitol, Arabitol ‚Äì These are nucleotides and sugars with limited direct associations to MetS.\nCaffeine ‚Äì May have protective effects against MetS but is not a biomarker.\nCotinine ‚Äì A nicotine metabolite, not directly related to MetS.\nMannitol, Lactose, Ascorbic Acid (Vitamin C) ‚Äì Not considered primary biomarkers for MetS.\n\nüìå Summary:\nStrongest biomarkers: TMAO, Choline, Serine, Glycine, Alanine, BCAAs (Isoleucine, Leucine), Taurine, Betaine, Acetylcarnitine, Glucose, Lactic Acid, Fructose.\nModerate biomarkers: Polyamines (Putrescine, Cadaverine), Tryptophan metabolites, Histamine, Hypotaurine.\nLess relevant metabolites: Nucleotides, sugar alcohols, caffeine.\n\n\n\n\nüìå Summary: Best Predictors of TMAO\nüî• Strongest Predictors: Choline, Betaine, Carnitine (Acetylcarnitine), Trimethylamine, Dimethylamine, Methylamine\nüü° Moderate Predictors: Serine, Methionine, Glycine, Taurine, Creatinine, Histamine, Hypotaurine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Choline\nüî• Strongest Predictors: Betaine, Serine, Methionine, Glycine, Acetylcarnitine\nüü° Moderate Predictors: Trimethylamine, Dimethylamine, Methylamine, Taurine, Histamine, Creatinine\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Lactic Acid, Pyruvic Acid, Xanthurenic Acid, Putrescine, Cadaverine\n\n\n\nüìå Summary: Best Predictors of Serine\nüî• Strongest Predictors: Glycine, Methionine, Asparagine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Choline, Betaine, Taurine, Histamine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Creatinine\n\n\n\nüìå Summary: Best Predictors of Glycine\nüî• Strongest Predictors: Serine, Methionine, Choline, Betaine, Glutamine, Aspartic Acid\nüü° Moderate Predictors: Taurine, Histamine, Acetylcarnitine, Creatinine, Lactic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Fructose, Glucose, Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine\n\n\n\nüìå Summary: Best Predictors of Alanine\nüî• Strongest Predictors: Pyruvic Acid, Aspartic Acid, Glutamine, Glutamate, Lactic Acid, Asparagine\nüü° Moderate Predictors: Serine, Glycine, Methionine, Creatinine, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Xanthurenic Acid, Putrescine, Cadaverine, Phenylalanine, Taurine\n\n\n\nüìå Summary: Best Predictors of Isoleucine\nüî• Strongest Predictors: Leucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Leucine\nüî• Strongest Predictors: Isoleucine, Valine, Aspartic Acid, Glutamine, Pyruvic Acid\nüü° Moderate Predictors: Alanine, Serine, Methionine, Creatinine, Lactic Acid, Glucose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Fructose\n\n\n\nüìå Summary: Best Predictors of Creatinine\nüî• Strongest Predictors: Creatine, Isoleucine, Leucine, Alanine, Glutamine, Glutamate\nüü° Moderate Predictors: Valine, Methionine, Aspartic Acid, Pyruvic Acid, Lactic Acid, Glucose, Fructose\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Taurine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\nüìå Summary: Best Predictors of Taurine\nüî• Strongest Predictors: Methionine, Hypotaurine, Glutamine, Glutamate, Aspartic Acid\nüü° Moderate Predictors: Serine, Alanine, Creatinine, Glucose, Fructose, Lactic Acid, Pyruvic Acid\n‚ö†Ô∏è Weaker Indirect Predictors: Histamine, Xanthurenic Acid, Putrescine, Mannose, Ribose\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†4: Correlation plot of metabolites considering all time points and nutrition models. In general the correlations are positive and high, which might be expected as the majority of data points correspond to one of the two nutrition models i.e.¬†metabolite concentrations are overall affected by the diet treatment.\n\n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\n\n\nNotable cases: [[plot_number]] Metabolite:\n\n[[11]] Choline\n[[12]] g_aminobutyric\n[[14]] Hypotaurine\n[[18]] Creatinine\n[[21]] Norvaline_Valine\n[[23]] Taurine\n[[28]] Leucine\n[[33]] Hypoxanthine\n[[42]] Phenylalanine\n[[51]] Tryptophan\n[[55]] Thymidine\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]\n\n\n\n\n\n\n\n\n\n\n[[24]]\n\n\n\n\n\n\n\n\n\n\n[[25]]\n\n\n\n\n\n\n\n\n\n\n[[26]]\n\n\n\n\n\n\n\n\n\n\n[[27]]\n\n\n\n\n\n\n\n\n\n\n[[28]]\n\n\n\n\n\n\n\n\n\n\n[[29]]\n\n\n\n\n\n\n\n\n\n\n[[30]]\n\n\n\n\n\n\n\n\n\n\n[[31]]\n\n\n\n\n\n\n\n\n\n\n[[32]]\n\n\n\n\n\n\n\n\n\n\n[[33]]\n\n\n\n\n\n\n\n\n\n\n[[34]]\n\n\n\n\n\n\n\n\n\n\n[[35]]\n\n\n\n\n\n\n\n\n\n\n[[36]]\n\n\n\n\n\n\n\n\n\n\n[[37]]\n\n\n\n\n\n\n\n\n\n\n[[38]]\n\n\n\n\n\n\n\n\n\n\n[[39]]\n\n\n\n\n\n\n\n\n\n\n[[40]]\n\n\n\n\n\n\n\n\n\n\n[[41]]\n\n\n\n\n\n\n\n\n\n\n[[42]]\n\n\n\n\n\n\n\n\n\n\n[[43]]\n\n\n\n\n\n\n\n\n\n\n[[44]]\n\n\n\n\n\n\n\n\n\n\n[[45]]\n\n\n\n\n\n\n\n\n\n\n[[46]]\n\n\n\n\n\n\n\n\n\n\n[[47]]\n\n\n\n\n\n\n\n\n\n\n[[48]]\n\n\n\n\n\n\n\n\n\n\n[[49]]\n\n\n\n\n\n\n\n\n\n\n[[50]]\n\n\n\n\n\n\n\n\n\n\n[[51]]\n\n\n\n\n\n\n\n\n\n\n[[52]]\n\n\n\n\n\n\n\n\n\n\n[[53]]\n\n\n\n\n\n\n\n\n\n\n[[54]]\n\n\n\n\n\n\n\n\n\n\n[[55]]\n\n\n\n\n\n\n\n\n\n\n[[56]]\n\n\n\n\n\n\n\n\n\n\n[[57]]\n\n\n\n\n\n\n\n\n\n\n[[58]]\n\n\n\n\n\n\n\n\n\n\n[[59]]\n\n\n\n\n\n\n\n\n\n\n[[60]]\n\n\n\n\n\n\n\n\n\n\n[[61]]\n\n\n\n\n\n\n\n\n\n\n[[62]]\n\n\n\n\n\n\n\n\n\n\n[[63]]\n\n\n\n\n\n\n\n\n\n\n[[64]]\n\n\n\n\n\n\n\n\n\n\n[[65]]\n\n\n\n\n\n\n\n\n\n\n[[66]]\n\n\n\n\n\n\n\n\n\n\n[[67]]\n\n\n\n\n\n\n\n\n\n\n[[68]]\n\n\n\n\n\n\n\n\n\n\n[[69]]\n\n\n\n\n\n\n\n\n\n\n[[70]]\n\n\n\n\n\n\n\n\n\n\n[[71]]\n\n\n\n\n\n\n\n\n\n\n[[72]]\n\n\n\n\n\n\n\n\n\n\n[[73]]\n\n\n\n\n\n\n\n\n\n\n[[74]]\n\n\n\n\n\n\n\n\n\n\n[[75]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#clinical-data-post-mortem",
    "href": "data_metabolic_syndrome.html#clinical-data-post-mortem",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "ContinuousCategorical\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      22 Continous Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n      Quantiles .05  .10  .25  .50  .75  .90  .95 \n    \n  \n  \n    Glucose\n\n34\n0\n27\n0.999\n149.7\n146.5\n25.54\n\n\n  118.6    131.3    140.0    146.0    153.8    181.3    202.1  \n    Glucose_œÑŒ±ŒπŒΩŒØŒµœÇ\n\n34\n0\n23\n0.997\n136.9\n137.5\n13.55\n\n\n  114.2    125.3    131.0    139.0    143.0    149.7    154.7  \n    Weight\n\n34\n0\n30\n0.999\n468.4\n463.5\n48.08\n\n\n  414.0    422.3    435.0    458.5    487.2    515.4    549.3  \n    BUN\n\n34\n0\n18\n0.996\n35.56\n31.5\n13.05\n\n\n  25.65    26.00    28.00    31.00    34.75    38.40    42.75  \n    Uric_Œëcid\n\n34\n0\n13\n0.988\n1.318\n1.25\n0.4364\n\n\n  0.800    0.860    1.025    1.250    1.475    1.800    2.105  \n    Creatinine\n\n34\n0\n14\n0.985\n0.4924\n0.435\n0.1554\n\n\n  0.380    0.393    0.410    0.425    0.460    0.490    0.497  \n    Tchol\n\n34\n0\n30\n0.999\n126.1\n124.5\n35.94\n\n\n  86.25    91.30    97.75    125.00    148.75    160.80    180.15  \n    Triglycerides\n\n32\n2\n30\n1.000\n267\n243.8\n174.9\n\n\n  90.2    115.7    148.0    231.0    320.0    496.1    597.2  \n    HDL\n\n34\n0\n23\n0.998\n36.94\n36.5\n10.47\n\n\n  24.30    27.30    30.25    35.00    41.75    48.00    54.40  \n    LDL\n\n34\n0\n14\n0.987\n9.147\n9\n3.995\n\n\n  5.00    5.30    7.00    8.00    11.75    14.70    16.00  \n    VLDL\n\n34\n0\n28\n0.999\n52.97\n48.5\n34.5\n\n\n  18.25    23.30    29.25    46.00    65.25    95.00    118.75  \n    TGL_HDL_ratio\n\n32\n2\n31\n1.000\n7.588\n6.37\n5.321\n\n\n  2.776    3.390    4.330    5.600    8.508    12.689    15.953  \n    Atherogenic_Index\n\n32\n2\n27\n0.999\n0.7975\n0.78\n0.2801\n\n\n  0.4415    0.5310    0.6375    0.7500    0.9275    1.1000    1.2015  \n    AST\n\n34\n0\n31\n1.000\n116.1\n107.5\n48.4\n\n\n  72.30    74.30    87.25    102.00    125.75    157.70    189.95  \n    ALT\n\n34\n0\n25\n0.998\n36.59\n36.5\n12.15\n\n\n  23.3    24.0    27.0    37.0    43.0    49.7    52.7  \n    ALP\n\n34\n0\n30\n0.999\n130.9\n129\n41.33\n\n\n  90.65    91.30    100.50    121.50    159.00    185.40    188.10  \n    ALB\n\n34\n0\n11\n0.975\n3.324\n3.35\n0.2909\n\n\n  2.965    3.030    3.200    3.350    3.475    3.670    3.700  \n    FERRITIN\n\n34\n0\n34\n1.000\n7.151\n6.97\n2.973\n\n\n  3.903    4.061    5.380    6.610    8.705    10.425    11.817  \n    LDH\n\n34\n0\n31\n1.000\n567.9\n537\n210.7\n\n\n  336.6    369.3    450.8    520.0    627.8    872.5    993.8  \n    AMYLASE\n\n34\n0\n34\n1.000\n2119\n2136\n373.4\n\n\n  1578    1719    1916    2176    2358    2496    2564  \n    Mg\n\n34\n0\n29\n0.999\n2.833\n2.77\n0.3814\n\n\n  2.497    2.520    2.590    2.755    2.962    3.074    3.131  \n    D3\n\n34\n0\n33\n1.000\n41.5\n41.75\n6.52\n\n\n  31.97    33.26    38.75    41.85    45.88    48.94    49.24  \n  \n  \n  \n\n\n\n\n\n\n\n  \n    \n      Clinical Data (post-mortem) Descriptives\n    \n    \n      3 Categorical Variables of 25 Variables, 34 Observations\n    \n    \n      Variable\n      Label\n      n\n      Missing\n      Distinct\n      Info\n      Mean\n      pMedian\n      Gini‚Äâ|Œî|\n       \n    \n  \n  \n    ID\n\n34\n0\n34\n\n\n\n\n\n\n    NutrMod\n\n34\n0\n3\n0.876\n2.147\n2\n0.8574\n\n\n    Na\n\n34\n0\n9\n0.953\n145.3\n145\n2.005\n\n\n  \n  \n  \n\n\n\n\n\n\n\nNote that p-values shown below are FDR adjusted at \\(a = 0.2\\) for all nutritional model comparisons i.e.¬†FDR_algc-adj, but not for any metabolite data (see modeling page for this).\nNotable cases: [[plot_number]] Clinical Metric:\n\n[[7]] Tchol\n[[9]] HDL\n[[10]] LDL\n[[11]] VLDL\n[[15]] ALT\n[[16]] ALP\n[[20]] Amylase\n\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]\n\n\n\n\n\n\n\n\n\n\n[[13]]\n\n\n\n\n\n\n\n\n\n\n[[14]]\n\n\n\n\n\n\n\n\n\n\n[[15]]\n\n\n\n\n\n\n\n\n\n\n[[16]]\n\n\n\n\n\n\n\n\n\n\n[[17]]\n\n\n\n\n\n\n\n\n\n\n[[18]]\n\n\n\n\n\n\n\n\n\n\n[[19]]\n\n\n\n\n\n\n\n\n\n\n[[20]]\n\n\n\n\n\n\n\n\n\n\n[[21]]\n\n\n\n\n\n\n\n\n\n\n[[22]]\n\n\n\n\n\n\n\n\n\n\n[[23]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#t2d-data",
    "href": "data_metabolic_syndrome.html#t2d-data",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "Note that p-values shown below are FDR adjusted at \\(a = 0.05\\) for all nutritional model comparisons but separately for each metabolite.\n\n\n[[1]]\n\n\n\n\n\n\n\n\n\n\n[[2]]\n\n\n\n\n\n\n\n\n\n\n[[3]]\n\n\n\n\n\n\n\n\n\n\n[[4]]\n\n\n\n\n\n\n\n\n\n\n[[5]]\n\n\n\n\n\n\n\n\n\n\n[[6]]\n\n\n\n\n\n\n\n\n\n\n[[7]]\n\n\n\n\n\n\n\n\n\n\n[[8]]\n\n\n\n\n\n\n\n\n\n\n[[9]]\n\n\n\n\n\n\n\n\n\n\n[[10]]\n\n\n\n\n\n\n\n\n\n\n[[11]]\n\n\n\n\n\n\n\n\n\n\n[[12]]",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "data_metabolic_syndrome.html#post-mortem-lipids",
    "href": "data_metabolic_syndrome.html#post-mortem-lipids",
    "title": "Data Description/Processing - Metabolic Syndrome In Rats",
    "section": "",
    "text": "See the Modeling page for both a univariate and multivariate analysis on lipids collected at post-mortem stage, as well as their differences amongst the nutritional models.",
    "crumbs": [
      "Sections",
      "Processing & EDA"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html",
    "href": "modeling_metabolic_syndrome.html",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "",
    "text": "Analysis‚Äô focus is to examine the effects of nutritional models (i.e.¬†plans) either directly on clinical measurements that might be associated with the metabolic syndrome or indirectly on metabolites that could have a potential association with the metabolic syndrome.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#methylhistidine---surrogate-of-atherogenic_index",
    "href": "modeling_metabolic_syndrome.html#methylhistidine---surrogate-of-atherogenic_index",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "3_Methylhistidine - Surrogate Of Atherogenic_Index",
    "text": "3_Methylhistidine - Surrogate Of Atherogenic_Index\nAtherogenic_Index is the log of TGL to HDL ratio.\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n                    n miss p.miss mean   sd median  p25   p75  min   max skew    kurt\n3_Methylhistidine0 34    0      0 7000 5924   6540 1890 10874  172 23045  0.8 -0.0026\nLactic_Acid0       34    0      0 2488  827   2211 1930  2942 1275  4483  1.1  0.4150\n------------------------------------------------------------------------------------------ \nNutrMod: C\n                   n miss p.miss mean   sd median  p25   p75  min   max skew kurt\n3_Methylhistidine0 8    0      0 9745 7363   9071 6285 11971  616 23045 0.61 0.33\nLactic_Acid0       8    0      0 2091  350   2048 1908  2250 1540  2729 0.42 1.12\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n                    n miss p.miss mean   sd median  p25   p75  min   max skew  kurt\n3_Methylhistidine0 13    0      0 7316 3975   6823 3191 10989 2500 13880 0.22 -1.42\nLactic_Acid0       13    0      0 2967  849   2890 2452  3350 1985  4483 0.68 -0.72\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n                    n miss p.miss mean   sd median  p25  p75  min   max skew   kurt\n3_Methylhistidine0 13    0      0 4994 6293   1686  910 6677  172 17117  1.3 -0.042\nLactic_Acid0       13    0      0 2253  821   1959 1857 2450 1275  4232  1.4  1.631\n\np-values\n                      pNormal pNonNormal\n3_Methylhistidine0 0.20096843  0.1051848\nLactic_Acid0       0.02130556  0.0125301\n\nStandardize mean differences\n                     average   1 vs 2    1 vs 3    2 vs 3\n3_Methylhistidine0 0.5151679 0.410518 0.6937425 0.4412432\nLactic_Acid0       0.8198847 1.348614 0.2560398 0.8550005\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\n3_Methylhistidine0 (mean (SD))\n6,999.96 (5,924.42)\n9,745.33 (7,362.69)\n7,316.45 (3,975.35)\n4,994.01 (6,293.14)\n0.201\n\n0.515\n\n\nLactic_Acid0 (median [IQR])\n2,210.92 [1,930.23, 2,941.61]\n2,048.40 [1,908.06, 2,250.37]\n2,890.13 [2,452.19, 3,350.35]\n1,959.41 [1,857.08, 2,449.71]\n0.013\nnonnorm\n0.820\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) 3_Methylhistidine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) 3_Methylhistidine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†1: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on 3_Methylhistidine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on 3_Methylhistidine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on 3_Methylhistidine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†2: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†3: 3_Methylhistidine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†4: 3_Methylhistidine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of 3_Methylhistidine at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†5: 3_Methylhistidine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) 3_Methylhistidine nutritional model differences versus 3_Methylhistidine at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) 3_Methylhistidine nutritional model differences versus 3_Methylhistidine at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†6: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#uracil---surrogate-of-ldl",
    "href": "modeling_metabolic_syndrome.html#uracil---surrogate-of-ldl",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Uracil - Surrogate Of LDL",
    "text": "Uracil - Surrogate Of LDL\n\n\n\n     ### Summary of continuous variables ###\n\nNutrMod: Overall\n           n miss p.miss  mean    sd median   p25   p75   min    max  skew kurt\nUracil0   34    0      0  7580  3357   7150  5268  9009  3924  22035  2.48 9.62\nCytidine0 34    0      0 73832 29671  67774 55517 77210 20877 150231  0.88 0.52\nPyruvic0  34    0      0  2104   813   2121  1486  2603     1   3870 -0.30 0.23\n------------------------------------------------------------------------------------------ \nNutrMod: C\n          n miss p.miss  mean    sd median   p25   p75   min   max   skew  kurt\nUracil0   8    0      0  5862  1505   5609  4540  7218  4279  8001  0.259 -2.00\nCytidine0 8    0      0 51297 19742  53805 42272 64773 20877 76669 -0.551 -0.77\nPyruvic0  8    0      0  1991   686   2016  1553  2485  1023  3038 -0.045 -0.81\n------------------------------------------------------------------------------------------ \nNutrMod: HC\n           n miss p.miss  mean    sd median   p25    p75   min    max  skew kurt\nUracil0   13    0      0  9615  4061   8722  7427  10209  5481  22035  2.65  8.3\nCytidine0 13    0      0 89183 34232  75154 63706 116552 47478 150231  0.52 -1.2\nPyruvic0  13    0      0  2385   947   2397  1957   2983     1   3870 -1.09  2.6\n------------------------------------------------------------------------------------------ \nNutrMod: HFHC\n           n miss p.miss  mean    sd median   p25   p75   min    max  skew  kurt\nUracil0   13    0      0  6603  2385   5937  4891  7726  3924  10951 0.933 -0.34\nCytidine0 13    0      0 72349 20629  67989 59255 73794 50170 116095 1.439  1.45\nPyruvic0  13    0      0  1893   711   2024  1319  2345   760   3060 0.074 -1.21\n\np-values\n             pNormal pNonNormal\nUracil0   0.01372648 0.00610947\nCytidine0 0.01249632 0.03328709\nPyruvic0  0.28322844 0.21145029\n\nStandardize mean differences\n            average    1 vs 2    1 vs 3    2 vs 3\nUracil0   0.8340753 1.2257422 0.3719465 0.9045372\nCytidine0 0.9980696 1.3558563 1.0426930 0.5956596\nPyruvic0  0.4014112 0.4758613 0.1408114 0.5875611\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOverall\nC\nHC\nHFHC\np\ntest\nSMD\n\n\n\n\nn\n34\n8\n13\n13\n\n\n\n\n\nUracil0 (median [IQR])\n7,150.09 [5,268.09, 9,009.22]\n5,608.51 [4,540.04, 7,217.58]\n8,721.63 [7,426.84, 10,208.85]\n5,937.38 [4,891.26, 7,725.84]\n0.006\nnonnorm\n0.834\n\n\nCytidine0 (mean (SD))\n73,831.80 (29,670.75)\n51,296.59 (19,741.57)\n89,182.76 (34,232.29)\n72,348.66 (20,628.86)\n0.012\n\n0.998\n\n\nPyruvic0 (mean (SD))\n2,103.88 (813.28)\n1,991.04 (686.47)\n2,384.56 (946.83)\n1,892.65 (710.91)\n0.283\n\n0.401\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Uracil at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Uracil at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†7: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Uracil. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Uracil. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Uracil. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†8: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†9: Uracil nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†10: Uracil nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Uracil at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†11: Uracil nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Uracil nutritional model differences versus Uracil at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Uracil nutritional model differences versus Uracil at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†12: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#choline---surrogate-of-tchol",
    "href": "modeling_metabolic_syndrome.html#choline---surrogate-of-tchol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Choline - Surrogate Of Tchol",
    "text": "Choline - Surrogate Of Tchol\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Choline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Choline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†13: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Choline. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Choline. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Choline. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†14: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†15: Choline nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†16: Choline nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Choline at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†17: Choline nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Choline nutritional model differences versus Choline at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Choline nutritional model differences versus Choline at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†18: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#creatinine---surrogate-of-buncreatininemg",
    "href": "modeling_metabolic_syndrome.html#creatinine---surrogate-of-buncreatininemg",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Creatinine - Surrogate Of BUN/Creatinine/Mg",
    "text": "Creatinine - Surrogate Of BUN/Creatinine/Mg\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Creatinine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Creatinine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†19: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Creatinine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Creatinine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Creatinine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†20: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†21: Creatinine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†22: Creatinine nutritional model differences based on raw data. Dashed horizontal line corresponds to the adjustment value of Creatinine at time 0.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†23: Creatinine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Creatinine nutritional model differences versus Creatinine at time 0 (trends) using raw data.\n\n\n\n\n\n\n\n\n\n\n\n(b) Creatinine nutritional model differences versus Creatinine at time 0 (trends) using model adjustment.\n\n\n\n\n\n\n\nFigure¬†24: Effect of adjusting to baseline metabolite value at time 0. Without adjustment, graph (a), the differences of the nutritional models depend on the baseline value. With adjustment, graph (b), the differences of the nutritional models do not depend on the baseline value i.e.¬†trend lines are parallel to each other.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#proline",
    "href": "modeling_metabolic_syndrome.html#proline",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Proline",
    "text": "Proline\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†25: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Proline. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Proline. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Proline. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†26: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†27: Proline nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†28: Proline nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#adenosine",
    "href": "modeling_metabolic_syndrome.html#adenosine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Adenosine",
    "text": "Adenosine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Adenosine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Adenosine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†29: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Adenosine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Adenosine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Adenosine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†30: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†31: Adenosine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†32: Adenosine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#mannose",
    "href": "modeling_metabolic_syndrome.html#mannose",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Mannose",
    "text": "Mannose\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Mannose at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Mannose at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†33: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Mannose. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Mannose. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Mannose. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†34: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†35: Mannose nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†36: Mannose nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#phenylalanine",
    "href": "modeling_metabolic_syndrome.html#phenylalanine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Phenylalanine",
    "text": "Phenylalanine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Phenylalanine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Phenylalanine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†37: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Phenylalanine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Phenylalanine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Phenylalanine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†38: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†39: Phenylalanine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†40: Phenylalanine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#adenine",
    "href": "modeling_metabolic_syndrome.html#adenine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Adenine",
    "text": "Adenine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Adenine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Adenine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†41: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Adenine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Adenine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Adenine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†42: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†43: Adenine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†44: Adenine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#fructose",
    "href": "modeling_metabolic_syndrome.html#fructose",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Fructose",
    "text": "Fructose\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Fructose at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Fructose at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†45: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Fructose. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Fructose. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Fructose. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†46: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†47: Fructose nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†48: Fructose nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#caffeine",
    "href": "modeling_metabolic_syndrome.html#caffeine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Caffeine",
    "text": "Caffeine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Caffeine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Caffeine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†49: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Caffeine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Caffeine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Caffeine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†50: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†51: Caffeine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†52: Caffeine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#indole_3_lactic_acid",
    "href": "modeling_metabolic_syndrome.html#indole_3_lactic_acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Indole_3_Lactic_Acid",
    "text": "Indole_3_Lactic_Acid\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Indole_3_Lactic_Acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Indole_3_Lactic_Acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†53: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Indole_3_Lactic_Acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Indole_3_Lactic_Acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Indole_3_Lactic_Acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†54: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†55: Indole_3_Lactic_Acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†56: Indole_3_Lactic_Acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#ascorbic_acid",
    "href": "modeling_metabolic_syndrome.html#ascorbic_acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Ascorbic_Acid",
    "text": "Ascorbic_Acid\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Ascorbic_Acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Ascorbic_Acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†57: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Ascorbic_Acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Ascorbic_Acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Ascorbic_Acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†58: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†59: Ascorbic_Acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†60: Ascorbic_Acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#taurine",
    "href": "modeling_metabolic_syndrome.html#taurine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Taurine",
    "text": "Taurine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Taurine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Taurine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†61: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Taurine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Taurine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Taurine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†62: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†63: Taurine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†64: Taurine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#methylamine",
    "href": "modeling_metabolic_syndrome.html#methylamine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Methylamine",
    "text": "Methylamine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Methylamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Methylamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†65: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Methylamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Methylamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Methylamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†66: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†67: Methylamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†68: Methylamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#alanine",
    "href": "modeling_metabolic_syndrome.html#alanine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Alanine",
    "text": "Alanine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Alanine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Alanine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†69: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Alanine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Alanine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Alanine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†70: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†71: Alanine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†72: Alanine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#ribose",
    "href": "modeling_metabolic_syndrome.html#ribose",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Ribose",
    "text": "Ribose\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Ribose at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Ribose at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†73: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Ribose. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Ribose. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Ribose. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†74: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†75: Ribose nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†76: Ribose nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#sarcosine",
    "href": "modeling_metabolic_syndrome.html#sarcosine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Sarcosine",
    "text": "Sarcosine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Sarcosine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Sarcosine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†77: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Sarcosine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Sarcosine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Sarcosine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†78: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†79: Sarcosine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†80: Sarcosine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#glucose",
    "href": "modeling_metabolic_syndrome.html#glucose",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Glucose",
    "text": "Glucose\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Glucose at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Glucose at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†81: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Glucose. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Glucose. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Glucose. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†82: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†83: Glucose nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†84: Glucose nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#monoisoamylamine",
    "href": "modeling_metabolic_syndrome.html#monoisoamylamine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Monoisoamylamine",
    "text": "Monoisoamylamine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Monoisoamylamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Monoisoamylamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†85: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Monoisoamylamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Monoisoamylamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Monoisoamylamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†86: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†87: Monoisoamylamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†88: Monoisoamylamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#mannitol",
    "href": "modeling_metabolic_syndrome.html#mannitol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Mannitol",
    "text": "Mannitol\nContains 11 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Mannitol at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Mannitol at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†89: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Mannitol. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Mannitol. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Mannitol. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†90: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†91: Mannitol nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†92: Mannitol nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#tryptamine",
    "href": "modeling_metabolic_syndrome.html#tryptamine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Tryptamine",
    "text": "Tryptamine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Tryptamine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Tryptamine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†93: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Tryptamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Tryptamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Tryptamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†94: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†95: Tryptamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†96: Tryptamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#methionine",
    "href": "modeling_metabolic_syndrome.html#methionine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Methionine",
    "text": "Methionine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Methionine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Methionine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†97: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Methionine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Methionine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Methionine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†98: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†99: Methionine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†100: Methionine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#arabitol",
    "href": "modeling_metabolic_syndrome.html#arabitol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Arabitol",
    "text": "Arabitol\nContains 19 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Arabitol at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Arabitol at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†101: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Arabitol. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Arabitol. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Arabitol. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†102: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†103: Arabitol nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†104: Arabitol nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#thymine",
    "href": "modeling_metabolic_syndrome.html#thymine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Thymine",
    "text": "Thymine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Thymine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Thymine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†105: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Thymine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Thymine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Thymine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†106: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†107: Thymine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†108: Thymine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#aspartic_acid",
    "href": "modeling_metabolic_syndrome.html#aspartic_acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Aspartic_Acid",
    "text": "Aspartic_Acid\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Aspartic_Acid at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Aspartic_Acid at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†109: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Aspartic_Acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Aspartic_Acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Aspartic_Acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†110: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†111: Aspartic_Acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†112: Aspartic_Acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#sorbitol",
    "href": "modeling_metabolic_syndrome.html#sorbitol",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Sorbitol",
    "text": "Sorbitol\nContains 39 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Sorbitol at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Sorbitol at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†113: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Sorbitol. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Sorbitol. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Sorbitol. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†114: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†115: Sorbitol nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†116: Sorbitol nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#theobromine",
    "href": "modeling_metabolic_syndrome.html#theobromine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Theobromine",
    "text": "Theobromine\nContains 51 non-detected cases i.e.¬†1s, out of 101 total cases post baseline.\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Theobromine at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Theobromine at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†117: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on Theobromine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on Theobromine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on Theobromine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†118: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†119: Theobromine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†120: Theobromine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#post-mortem-data",
    "href": "modeling_metabolic_syndrome.html#post-mortem-data",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Post-Mortem Data",
    "text": "Post-Mortem Data\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†121: PCA of post-mortem clinical data. Variable and rat id biplot contributions. Variable contribution emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†122: PCA of post-mortem clinical data. Variable and rat id biplot contributions. Nutritional model separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†123: PCA of post-mortem clinical data. Explained variation distribution of the first 10 components.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) PCA of post-mortem clinical data. Contributions of variables to component 1.\n\n\n\n\n\n\n\n\n\n\n\n(b) PCA of post-mortem clinical data. Contributions of variables to component 2.\n\n\n\n\n\n\n\n\n\n\n\n(c) PCA of post-mortem clinical data. Contributions of variables to component 3\n\n\n\n\n\n\n\nFigure¬†124: A reference dashed line is also shown on the barplot. This reference line corresponds to the expected value if the contribution where uniform. For a given dimension, any variable with a contribution above the reference line could be considered as important in contributing to the dimension.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†125: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 1 and 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†126: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 1 and 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†127: PCA on post-mortem clinical data for viewing the separation among nutritional models. Focus on components 2 and 4.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#longitudinal-data",
    "href": "modeling_metabolic_syndrome.html#longitudinal-data",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Longitudinal Data",
    "text": "Longitudinal Data\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†128: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Variable contribution emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†129: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Time Point (Month) separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†130: PCA of metabolites‚Äô data. Variable and rat id biplot contributions. Nutritional Model separation emphasis.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†131: MFA of metabolites‚Äô data. Biplot of individuals and qualitative variables.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†132: MFA of metabolites‚Äô data. Explained variation distribution of the first 10 components.\n\n\n\n\n\n\n\n\n\n\n\n\nPer Time or Month - Unadjusted for Time 0\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†133: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†134: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 1.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†135: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 2.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†136: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 3.\n\n\n\n\n\n\n\n\nPer Time or Month - Adjusted for Time 0\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†137: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 0. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†138: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 1. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†139: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 2. Adjusted for the median value of each metabolite at time 0.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure¬†140: PCA of metabolites‚Äô data. Biplot of individuals and variables at time 3. Adjusted for the median value of each metabolite at time 0.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#dopamine",
    "href": "modeling_metabolic_syndrome.html#dopamine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Dopamine",
    "text": "Dopamine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†215: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on dopamine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on dopamine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on dopamine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†216: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†217: dopamine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†218: dopamine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "notes_metabolic_syndrome.html",
    "href": "notes_metabolic_syndrome.html",
    "title": "notes_metabolic_syndrome",
    "section": "",
    "text": "References & Research Notes\n\nhttps://stats.stackexchange.com/questions/637773/why-does-harrell-argue-for-ignoring-y-during-data-reduction\n\nOne of the worst things you can do with data is to take a huge number of collinear features and predict to find the ‚Äúright‚Äù features that predict Y.\n\nhttps://stats.stackexchange.com/questions/296164/does-it-make-sense-to-run-a-stepwise-regression-on-components-estimated-through\nhttps://stats.stackexchange.com/questions/441860/isnt-it-futile-to-try-to-fix-multicollinearity\n\nIf the goal is prediction then your proposed solution sounds agreeable, but inference is a whole other beast.\nThe fact is that the theory, for example concerning sampling distributions of coefficients, is not capable of conditioning in such model selection procedures. Frank Harrell talks a little bit about this in Regression Modelling Strategies in the section about stepwise regression.\nStatistics is not an algorithmic truth generating process. You need to be able to say ‚ÄúI think X is related to the outcome‚Äù in order to make inferences of the nature statistics affords us.\n\nhttps://stats.stackexchange.com/questions/515412/circular-reasoning-in-harrell-bbr-18-19\n\nyou agree and understand why we should prefer c-index and likelihood ratio chi square (LHRCS) to classification accuracy\n\nhttps://stats.stackexchange.com/questions/621395/how-can-i-automatically-perform-multiple-linear-regressions-in-r-to-identify-the\n\nMy advice is to NOT automate this. There are a variety of methods to do automated model selection (forward, backward, stepwise). Of these, the only ones that I would use are penalized methods such as LASSO. What you seem to want is all subsets regression, which is possible in R. There are a few methods (you can Google ‚Äúall subsets regression in R‚Äù to find some) but these aren‚Äôt good. P values will be too low, standard errors too small, models too complex and parameter estimates biased away from 0. (See Frank Harrell‚Äôs book Regression Modeling Strategies for details, examples, proofs and so on).\nWorse: It stops you from thinking.\nChoose models that make sense. Just a few of them. Compare those. You‚Äôve already shown us that you‚Äôve done some of this.\nIf you are interested in uncovering interactions, then trees (or some offshoot of them) may be good. I‚Äôm not sure why you are opposed.\nIf you want to look at combinations of variables, and don‚Äôt need to include the original variables, then partial least squares might be good. From the variables you‚Äôve listed, it looks like the first component will be ‚Äúsize‚Äù, but that may be fine.\nHarrell: The worst thing I can think of saying about variable selection methods is that they fail at what they pretend to do. They can‚Äôt select the right variables. And small changes in the dataset result in different variables selected. They there is their destruction of standard errors ‚Ä¶\n\nhttps://stats.stackexchange.com/questions/201061/whats-wrong-with-data-guided-modeling-in-regression\nhttps://stats.stackexchange.com/questions/200242/minimum-number-of-observations-needed-for-penalized-regression/200368#200368\n\nPenalized estimation can be used for very small sample sizes; it‚Äôs just that the estimates will be shrunk to the mean very heavily, so the estimates will be conservative. But the intercept in the model is not shrunk\n\nhttps://stats.stackexchange.com/questions/491861/penalized-or-standard-logistic-regression"
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#phenol-sulfate",
    "href": "modeling_metabolic_syndrome.html#phenol-sulfate",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Phenol Sulfate",
    "text": "Phenol Sulfate\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†219: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on phenol_sulfate. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on phenol_sulfate. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on phenol_sulfate. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†220: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†221: phenol_sulfate nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†222: phenol_sulfate nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#p-hydroxyphenyl-acetic-acid",
    "href": "modeling_metabolic_syndrome.html#p-hydroxyphenyl-acetic-acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "P Hydroxyphenyl Acetic Acid",
    "text": "P Hydroxyphenyl Acetic Acid\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†223: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on p_hydroxyphenyl_acetic_acid. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on p_hydroxyphenyl_acetic_acid. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on p_hydroxyphenyl_acetic_acid. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†224: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†225: p_hydroxyphenyl_acetic_acid nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†226: p_hydroxyphenyl_acetic_acid nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#tyramine",
    "href": "modeling_metabolic_syndrome.html#tyramine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Tyramine",
    "text": "Tyramine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†227: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on tyramine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on tyramine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on tyramine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†228: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†229: tyramine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†230: tyramine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#tyrosine",
    "href": "modeling_metabolic_syndrome.html#tyrosine",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Tyrosine",
    "text": "Tyrosine\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Proline at Month 0 : Baseline\n\n\n\n\n\n\n\n\n\n\n\n(b) Proline at Months 1-3 : Treatment\n\n\n\n\n\n\n\nFigure¬†231: Proportion of nutritional model instances per metabolite concentration quantile (denoted by the average value of concentrations within each quantile).\n\n\n\n¬†\n\n\n\n\n\n\n\n\n\n\n\n(a) Nutritional Model Odds Ratio on tyrosine. HC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Nutritional Model Odds Ratio on tyrosine. HFHC vs C difference\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Nutritional Model Odds Ratio on tyrosine. HFHC vs HC difference\n\n\n\n\n\n\n\nFigure¬†232: Average Treatment Effects (ATE)\n\n\n\n¬†\n\n\n\n\n\n\n\n\nFigure¬†233: tyrosine nutritional model differences from baseline at t0 (trends)\n\n\n\n\n\n¬†\n¬†\n\n\n\n\n\n\n\n\nFigure¬†234: tyrosine nutritional model differences from baseline at t0 (split view). Points denote median concentrations and lines denote the corresponding central 80% likelihood intervals.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#p-hydroxyphenyllactic-acid",
    "href": "modeling_metabolic_syndrome.html#p-hydroxyphenyllactic-acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "P Hydroxyphenyllactic Acid",
    "text": "P Hydroxyphenyllactic Acid",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#indole3lactic-acid",
    "href": "modeling_metabolic_syndrome.html#indole3lactic-acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Indole3lactic Acid",
    "text": "Indole3lactic Acid",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#p-hba",
    "href": "modeling_metabolic_syndrome.html#p-hba",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "P Hba",
    "text": "P Hba",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#anthranilic-acid",
    "href": "modeling_metabolic_syndrome.html#anthranilic-acid",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Anthranilic Acid",
    "text": "Anthranilic Acid",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling_metabolic_syndrome.html#indoxyl-sulfate",
    "href": "modeling_metabolic_syndrome.html#indoxyl-sulfate",
    "title": "Modeling & Assessing Metabolic Syndrome In Rats (Metabolite Added Value)",
    "section": "Indoxyl Sulfate",
    "text": "Indoxyl Sulfate",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  }
]